Exelixis (EXEL) Operating Leases (2010 - 2026)
Exelixis' (EXEL) quarterly Operating Leases came in at $169.5 million in Q2 2026, down 9.4% year-on-year from $187.1 million in Q2 2025, and down 2.02% quarter-over-quarter from $173.0 million in Q1 2026.
Exelixis (EXEL) Operating Leases (2010 - 2026) Analysis & Trends
Exelixis' Operating Leases history runs 15 years deep, the most recent figure standing at $169.5 million for Q2 2026.
- On a quarterly basis, Operating Leases fell 9.4% year-over-year to $169.5 million in Q2 2026; TTM through Apr 2026 was $169.5 million, a 9.4% decrease from a year earlier, with the FY2026 full-year figure at $173.0 million, down 19.83% from the prior year.
- Operating Leases eased to $169.5 million in Q2 2026 per EXEL's latest filing, from $173.0 million in the prior quarter.
- Across five years, Operating Leases topped out at $215.8 million in Q1 2025 and bottomed at $50.6 million in Q2 2022.
- The 5-year median for Operating Leases is $187.1 million (2025), against an average of $180.2 million.
- Across the five-year window, Operating Leases jumped 305.35% in 2022 and decreased 19.83% in 2026, its largest moves.
- Year by year, Operating Leases stood at $207.8 million in 2022, then advanced by 3.77% to $215.7 million in 2023, then declined by 9.84% to $194.4 million in 2024, then decreased by 9.25% to $176.5 million in 2025, then decreased by 3.92% to $169.5 million in 2026.
- Per Business Quant, the three latest EXEL Operating Leases figures stand at $169.5 million (Q2 2026), $173.0 million (Q1 2026), and $176.5 million (Q4 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Exelixis | 14.38 Bn | 13.60 Bn | 590.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 3, 2026 | 169.54 Mn |
| Jan 2, 2026 | 173.04 Mn |
| Oct 3, 2025 | 176.46 Mn |
| Jul 4, 2025 | 179.84 Mn |
| Apr 4, 2025 | 187.13 Mn |
| Jan 3, 2025 | 215.83 Mn |
| Sep 27, 2024 | 194.45 Mn |
| Jun 28, 2024 | 198.02 Mn |
| Mar 29, 2024 | 201.47 Mn |
| Dec 29, 2023 | 215.66 Mn |
| Sep 29, 2023 | 190.86 Mn |
| Jun 30, 2023 | 194.69 Mn |
| Mar 31, 2023 | 186.95 Mn |
| Dec 30, 2022 | 207.83 Mn |
| Sep 30, 2022 | 159.84 Mn |
| Jul 1, 2022 | 161.02 Mn |
| Apr 1, 2022 | 50.64 Mn |
| Dec 31, 2021 | 51.27 Mn |
| Oct 1, 2021 | 52.25 Mn |
| Jul 2, 2021 | 53.22 Mn |